Skip to content
Precision for Medicine
Contact Us
false false
CRO global overview CRO global overview

Global CRO Services

Global reach, local precision: Comprehensive solutions to power your clinical trials worldwide.
At Precision for Medicine, we merge global reach with local insight to navigate the complexities of clinical trials with unparalleled expertise and precision. From full-service study execution to functional service solutions, our global scale and tailored strategies are crafted to enhance every phase of your clinical trial journey.

Global scale with Precision Clinical Trial Services

Precision for Medicine offers unmatched global clinical trial services, harnessing our extensive international presence to meet the comprehensive needs of your research. With expertise in over 50 countries, our local specialists provide invaluable insights and regulatory compliance, ensuring seamless execution across borders. Our global scale, combined with precise local knowledge, accelerates the progress of your clinical trials with efficiency and expertise.

Clinical Reach

Comprehensive clinical trial support: From strategy to execution

  • Clinical Development Strategy

    Unlock the full potential of your clinical trials with our bespoke Clinical Development Strategy, designed to navigate complexities and accelerate success.
    Explore

    Services Offered:

    • Clinical Development Planning
    • Clinical Trial Design
    • Biomarker Trial Strategies
    • Basket, Master & Umbrella trials
    Explore
    AdobeStock_135807945

  • Full-Service CRO

    Experience the seamless integration of comprehensive trial management with our Full-Service CRO, where every detail is expertly managed to drive your study's success.
    Explore

    Services include, but are not limited to:

    • Full-service Study Management
    • Study Start-up & Feasibility
    • Clinical Monitoring
    • Medical Monitoring
    • Drug Safety & Pharmacovigilance
    • Data Management
    • Biostatistics
    Explore
    particles-global-cro

  • Precision FSP

    Enhance your clinical trial's efficiency with Precision’s Functional Service Provider (FSP) solutions, offering specialized support tailored to your project's unique needs.
    Explore

    Solutions Offered:

    • FSP Data Management
    • FSP Biostatistics
    • FSP Statistical Programming
    • FSP Medical Writing
    Explore
    iStock-1297146235

Deep experience with debilitating disease and unique modalities

Like you, we understand that there’s a patient throughout the development pathway. Supporting our partners to bring innovative treatments to patients is our purpose. Leverage our experience in these therapeutic areas.

Oncology Explore Rare Diseases Explore Autoimmune Explore Gene Therapy Explore Cell Therapy Explore

  • Delivering Excellence in The Americas, Europe, and APAC

  • iStock-1406960186

    The Americas CRO

    Harnessing the diverse clinical landscape of The Americas to deliver research excellence and transformative health solutions.
    Explore
  • iStock-1449138552

    Europe CRO

    Leveraging Europe's advanced healthcare systems to conduct sophisticated and efficient clinical trials.
    Explore
  • iStock-1694163174

    APAC CRO

    In APAC, our trials tap into cutting-edge technology and vast patient populations to drive global health progress.
    Explore

Specialized capabilities in every stage of clinical development

An integrated infrastructure that reduces the inefficiencies inherent in complex development

  • Discover Explore
    clinical-trial-support

    Global CRO Services

    A recognized leader in oncology and rare diseases with rich experience in complex trials

    Explore
  • Discover Explore
    specialty-lab-services

    Laboratory
    Services

    Experts in translational and biomarker sciences with worldwide specialty labs and central lab services that are enabling breakthroughs.

    Explore

Discover actionable insights from thought leaders on the front lines of research.

Call to action
Read: Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM) Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

Clinical Trials

Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat
Discover
Read: Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM) Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

Clinical Trials

Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat
Discover
Read: Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

Clinical Trials

Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=187570680222, hs_child_table_id=0, hs_updated_at=1742413198455, hs_published_at=1748379090824, description=Christine has been ensuring high performance delivery of clinical research projects for more than 23 years. During this time, she has successfully led diverse teams across various cancer indications including renal, pancreatic, melanoma, lung, head and neck, breast, multiple myeloma, extra-nodal NK/T lymphoma, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma. Within the CRO setting she also supported the strategic development of over 50 hematology/oncology programs including complex Phase 1 projects in immuno-oncology and autologous cell therapy. She also led the establishment of a novel oncology research infrastructure which accelerated study activations for Phase 1 solid tumor studies. Christine obtained her master’s degree in public health at the University of Texas where she also trained in the development and implementation of clinical and epidemiologic research at the Coordinating Center for Clinical Trials as well as the Center for Occupational and Environment Health., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Christine%20Lusk-1.png',altText='Christine Lusk-1',fileId=187579105870}, lastname=Lusk, hs_initial_published_at=1742410730688, hs_created_by_user_id=26433386, hs_created_at=1742410650472, hs_is_edited=false, hs_deleted_at=0, name=Christine, job=Director, Project Management, slug=christine-lusk, hs_updated_by_user_id=51739740}, second={hs_id=190691157084, hs_child_table_id=0, hs_updated_at=1748379058655, hs_published_at=1748379090824, description=Over the last 15 years, Megan has played a key role in advancing multiple oncology compounds through various stages of development, across numerous tumor types. Having worked at both biotech and CRO companies, Megan brings a comprehensive understanding of clinical operations and drug development. Megan maintains a focus on accelerating the development of innovative cancer therapies to improve patient outcomes worldwide., avatar=Image{width=3024,height=4032,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Megan%20Knoch.jpg',altText='Megan Knoch',fileId=190688034156}, lastname=Knoch, hs_initial_published_at=1748379090824, hs_created_by_user_id=26433386, hs_created_at=1748379018316, hs_is_edited=false, hs_deleted_at=0, name=Megan, slug=megan-knoch, hs_updated_by_user_id=26433386}, third={}})
  • Christine L. avatar

    Christine L.
  • Megan K. avatar

    Megan K.
Discover